Articles tagged "Highly-sensitized"

2022 American Transplant Congress
Regulatory T Cells Suppress Memory IFN-Gamma Production in Highly Sensitised Patients
C. Dudreuilh¹, S. Basu¹, O. Shaw², H. Burton¹, C. Domingo-Vila¹, T. Tree¹, G. Lombardi¹, C. Scotta¹, A. Dorling¹
¹King's College London, London, United Kingdom, ²Viapath Clinical Transplantation Laboratory, Guy's Hospital, London, United Kingdom
*Purpose: Highly sensitized patients (HS) present worse long-term outcome after transplantation compared to those without donor-specific antibodies (DSA). It has been suggested that desensitisation using…
2022 American Transplant Congress
Clazakizumab® (anti-il-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow Up
A. Vo¹, J. Tang¹, N. Ammerman¹, E. Huang¹, X. Zhang², M. Haas³, A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, M. Gillespie¹, N. Badash¹, S. Jordan¹
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ²HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a cytokine critical for B-cell activation and IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6.…
2022 American Transplant Congress
CIAT: A New Kidney Exchange Program with Better Options for Highly Sensitized and Long Waiting Patients
M. d. Klerk¹, J. Kal¹, D. L. Roelen², M. Betjes¹, A. Weerd de¹, M. Reinders¹, M. Kho¹, K. Glorie³, J. I. Roodnat¹
¹Internal Medicine, Erasmus MC Transplant Institute, Rotterdam, Netherlands, ²Immunology, Leids UMC, Netherlands, ³Econometrics, EUR, Rotterdam, Netherlands
*Purpose: A number of alternative, both living and deceased donor kidney transplant programs have been developed for incompatible pairs and difficult to match patients. The…
2022 American Transplant Congress
Evaluation of Hepatitis C Positive Donor to Hepatitis C Negative Recipient Kidney Transplant in a Highly Sensitized Patient Population
A. T. Iaria, M. Martin, A. Hietpas, I. Tang, S. Koppe, I. Tzvetanov, E. Benedetti, C. Muran
University of Illinois at Chicago, Chicago, IL
*Purpose: This study assessed outcomes of hepatitis C virus (HCV) donor positive to recipient negative (D+/R-) kidney transplants (KT) in high immunologic risk patients. Literature…
2022 American Transplant Congress
Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus
R. Zhang¹, S. Ge¹, M. Chu¹, J. Kahwaji², A. Karasyov¹, D. Lovato¹, A. Vo², J. Choi², M. Toyoda¹, S. Jordan²
¹Transplant Immunology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Post-transplant immunosuppression with “everolimus + reduced dose tacrolimus” (Ev + Taclow) is reported to reduce the risk of viral infections compared to standard doses…
2022 American Transplant Congress
Stem Cell Donor-Derived CPRA Better Reflects Sensitization Than Current CPRA
K. Lindblad¹, C. Murphey², P. Lalli³, J. Lunz⁴, L. Gragert⁵
¹UNOS, Richmnd, VA, ²Southwest Immunodiagnostics, Inc., San Antonio, TX, ³Carolinas Medical Center, Charlotte, NC, ⁴LifeLink Foundation Transplant Immunology Lab, Tampa, FL, ⁵Tulane University School of Medicine, New Orleans, LA
*Purpose: The OPTN Histocompatibility Committee proposes replacing the current calculated panel reactive antibody (CPRA), based on HLA haplotype frequencies from ~14,000 deceased kidney donors, with…
2022 American Transplant Congress
Characterizing the Landscape of Cancer Risk Following HLA-Incompatible Living Donor Kidney Transplantation
J. D. Motter¹, K. Jackson¹, K. Yu², R. M. Pfeiffer², A. Massie¹, J. Garonzik-Wang³, D. Segev¹, E. A. Engels²
¹Johns Hopkins University, Baltimore, MD, ²National Cancer Institute, Bethesda, MD, ³University of Wisconsin-Madison, Madison, WI
*Purpose: Incompatible living donor kidney transplant recipients (ILDKTr) require desensitization to facilitate transplantation across donor-specific antibody (DSA); however, this substantial upfront immunosuppression may result in…
2022 American Transplant Congress
Long-Term Outcomes of Crossmatch Positive Simultaneous Liver Kidney Transplants in the United States
S. Riad¹, E. Aby¹, S. Jackson², P. Nguyen³, N. Lim¹, J. Lake¹
¹Medicine, University of Minnesota, Minneapolis, MN, ²Mhealth-Fairview, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: The long-term results of crossmatch positive (XM+) simultaneous liver-kidney (SLK) transplants are conflicting. We examined the association between crossmatch (XM) status and SLK outcomes…
2022 American Transplant Congress
Outcomes of Hlai Kidney Transplants in Patients with Cpra 100% After Desensitization
A. A. Vo¹, J. Tang¹, S. Williamson¹, C. Meyers¹, E. Huang¹, X. Zhang², M. Haas³, A. Peng¹, R. Najjar¹, S. Supreet¹, N. Ammerman¹, K. Lim¹, M. Gillespie¹, N. Badash¹, S. Jordan¹
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ²HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: The KAS implementation was aimed at increasing access to kidney transplantation in highly HLA sensitized (HS) patients. However, combining desensitization (DES) + KAS could…
2022 American Transplant Congress
Successful Outcome of Highly Sensitized Patients After Heart Transplantation Under RATG Regimen
G. Esmailian, T. Singer-Englar, J. Patel, M. Kittleson, S. Kim, N. Patel, D. Chang, E. Kransdorf, F. Esmailian, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Highly sensitized patients (panel reactive antibody [PRA] ≥50%) are known to be at risk for poor outcome after heart transplantation (HTx). In our program,…

1
2
3
…
15
Next Page »